BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 9661602)

  • 1. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis.
    Azziz R; Black V; Hines GA; Fox LM; Boots LR
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2317-23. PubMed ID: 9661602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen response to hypothalamic-pituitary-adrenal stimulation with naloxone in women with myotonic muscular dystrophy.
    Buyalos RP; Jackson RV; Grice GI; Hockings GI; Torpy DJ; Fox LM; Boots LR; Azziz R
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3219-24. PubMed ID: 9745431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenocortical secretion of dehydroepiandrosterone in healthy women: highly variable response to adrenocorticotropin.
    Azziz R; Fox LM; Zacur HA; Parker CR; Boots LR
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2513-7. PubMed ID: 11397848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of aging on adrenal function in the human: responsiveness and sensitivity of adrenal androgens and cortisol to adrenocorticotropin in premenopausal and postmenopausal women.
    Parker CR; Slayden SM; Azziz R; Crabbe SL; Hines GA; Boots LR; Bae S
    J Clin Endocrinol Metab; 2000 Jan; 85(1):48-54. PubMed ID: 10634362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome.
    Demitrack MA; Dale JK; Straus SE; Laue L; Listwak SJ; Kruesi MJ; Chrousos GP; Gold PW
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1224-34. PubMed ID: 1659582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in the hypothalamic-pituitary-ovarian and the hypothalamic-pituitary-adrenal axes in athletic women.
    Loucks AB; Mortola JF; Girton L; Yen SS
    J Clin Endocrinol Metab; 1989 Feb; 68(2):402-11. PubMed ID: 2537332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome.
    Yildiz BO; Woods KS; Stanczyk F; Bartolucci A; Azziz R
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5558-62. PubMed ID: 15531511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the origin of the elevated 17-hydroxyprogesterone levels after adrenal stimulation in hyperandrogenism.
    Azziz R; Rafi A; Smith BR; Bradley EL; Zacur HA
    J Clin Endocrinol Metab; 1990 Feb; 70(2):431-6. PubMed ID: 2137133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome.
    Lanzone A; Fulghesu AM; Guido M; Cucinelli F; Caruso A; Mancuso S
    Fertil Steril; 1997 Jan; 67(1):34-9. PubMed ID: 8986680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone.
    Lanzone A; Guido M; Ciampelli M; Fulghesu AM; Pavone V; Proto C; Caruso A; Mancuso S
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):73-7. PubMed ID: 8796141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans.
    Dorin RI; Ferries LM; Roberts B; Qualls CR; Veldhuis JD; Lisansky EJ
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3883-91. PubMed ID: 8923833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome.
    Puurunen J; Piltonen T; Jaakkola P; Ruokonen A; Morin-Papunen L; Tapanainen JS
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1973-8. PubMed ID: 19318449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess.
    Moran C; Reyna R; Boots LS; Azziz R
    Fertil Steril; 2004 Jan; 81(1):126-31. PubMed ID: 14711555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of adrenocorticotropin and adrenal steroid responses to corticotropin-releasing hormone versus metyrapone testing in patients with hypopituitarism.
    Riddick L; Chrousos GP; Jeffries S; Pang S
    Pediatr Res; 1994 Aug; 36(2):215-20. PubMed ID: 7970937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative sensitivity and responsivity of serum cortisol and two adrenal androgens to alpha-adrenocorticotropin-(1-24) in normal and obese, nonhirsute, eumenorrheic women.
    Komindr S; Kurtz BR; Stevens MD; Karas JG; Bittle JB; Givens JR
    J Clin Endocrinol Metab; 1986 Oct; 63(4):860-4. PubMed ID: 3018027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-related differences in stimulated hypothalamic-pituitary-adrenal axis during induced gonadal suppression.
    Roca CA; Schmidt PJ; Deuster PA; Danaceau MA; Altemus M; Putnam K; Chrousos GP; Nieman LK; Rubinow DR
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4224-31. PubMed ID: 15886244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome.
    Ditkoff EC; Fruzzetti F; Chang L; Stancyzk FZ; Lobo RA
    J Clin Endocrinol Metab; 1995 Feb; 80(2):603-7. PubMed ID: 7852527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome.
    Romualdi D; Giuliani M; Draisci G; Costantini B; Cristello F; Lanzone A; Guido M
    Fertil Steril; 2007 Jul; 88(1):131-8. PubMed ID: 17336978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.